# Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

> **NCT03620643** · PHASE2 · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 33 (actual)

## Conditions studied

- Lobular Breast Carcinoma
- Gastric Cancer
- Triple Negative Breast Cancer
- CDH1 Gene Mutation

## Interventions

- **DRUG:** Crizotinib Oral Capsule [Xalkori]
- **DRUG:** Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]

## Key facts

- **NCT ID:** NCT03620643
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-09
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-10-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03620643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03620643, "Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03620643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*